Internal summary of official changes affecting NAM validation, qualification, or regulatory use.
For site planning only, not legal or regulatory advice. Items without a dated official source and a clear process impact were excluded.
ICCVAMOrganizational change2026-06-15
NICEATM Moved Into the New NIH Office of Research Innovation, Validation, and Application (ORIVA)
NIH announced that NICEATM, the scientific-support arm behind ICCVAM's cross-agency validation work, will continue as a division of the newly created NIH Office of Research Innovation, Validation, and Application (ORIVA), which coordinates NIH-wide development, validation, and scaling of human-based NAMs.
- The cross-agency validation route continues through ICCVAM and NICEATM, now organized under ORIVA, so method developers still engage NICEATM and ICCVAM during prevalidation and validation.
- Placing NICEATM under an office chartered to scale NAM validation across NIH strengthens the institutional backing for the ICCVAM evaluation pathway.
- This is an organizational change rather than a change to the ICCVAM validation steps themselves.
Official sourceNIH news release on the ORIVA office, June 15, 2026
EPAList update and process change2026-06-02
EPA Adds 13 New Approach Methods to Its TSCA List and Opens a Nomination Process
EPA added 13 externally validated NAMs to its list of methods accepted for TSCA and FIFRA testing (its first list update since 2021) and introduced a streamlined process for stakeholders to nominate additional NAMs, evaluated on relevance, reliability, transparency, and reproducibility. Examples include a reconstructed-human-cell eye-hazard test, a 3D-tissue phototoxicity method, and OECD-validated dermal-sensitization combinations.
- EPA now publishes an updated, concrete list of acceptable NAMs, so sponsors can check whether a method is already recognized before designing a submission.
- The new nomination process gives method developers a defined route to have a NAM evaluated for EPA use, which is a process change for the chemical-safety domain.
- It reinforces the EPA pathway's emphasis on relevance, reliability, and transparency for a defined regulatory endpoint.
- Roadmap change applied 2026-07-08: added an EPA pathway step (now step 2) to check EPA's accepted-NAMs list and nominate a method when it is not yet listed. The earlier five-step EPA pathway had no explicit list-or-nominate step.
Official sourceEPA announcement on NAMs under TSCA and FIFRA, June 2, 2026
FDAProgress report2026-04-20
Reducing Animal Testing in Nonclinical Studies: Year One Progress and the Path Forward
FDA published a one-year progress report on its 2025 roadmap to reduce animal testing. It reported qualifying the first AI-based (in silico) drug development tool for regulatory use, launching a public database that clarifies which alternative methods FDA considers acceptable, and updating monoclonal-antibody guidance to reduce or remove six-month nonhuman primate studies.
- The first AI/in silico tool qualification shows the FDA qualification pathways now producing accepted NAM tools, not just accepting NAM data case by case.
- The new acceptability database gives sponsors a reference for which methods FDA already treats as usable, which is relevant to both the direct submission-use and formal qualification routes.
- This report builds on the March 2026 general NAM validation draft guidance and confirms the direction of travel rather than changing the underlying validation expectations.
Official sourceFDA press announcement and year-one report, April 20, 2026
FDADraft guidance2026-03-19
General Considerations for the Use of New Approach Methodologies in Drug Development
FDA issued draft guidance describing a general validation framework for NAMs in drug development and explicitly encouraged use of NAM data in regulatory submissions when the method is fit for purpose and improves the human relevance and predictivity of nonclinical evidence.
- This is the clearest recent FDA change separating NAM validation for submission use from formal DDT qualification.
- The guidance emphasizes context of use, human biological relevance, technical characterization, reliability, and fit-for-purpose validation rather than treating qualification as the only route.
- The roadmap now needs a direct submission-use route in addition to ISTAND and DDT qualification pathways.
Official sourceFDA guidance document and Federal Register notice, March 19, 2026
FDADraft guidance2025-12-02
Monoclonal Antibodies: Streamlined Nonclinical Safety Studies
FDA issued draft guidance for certain monospecific monoclonal antibodies stating that six-month non-human primate toxicity studies can be reduced or eliminated for specific product types and that knowledge-based risk assessments may integrate computational toxicology, organoid systems, and real-world human safety data in regulatory decision-making.
- This is a product-specific change rather than a general NAM validation framework, but it materially changes how FDA can accept non-animal evidence for some antibody programs.
- The draft guidance shows FDA moving from routine long-duration primate studies toward risk-based use of human-relevant NAM evidence for defined products.
- Any roadmap language about FDA expectations for biologics should now distinguish general NAM validation principles from this narrower monoclonal-antibody policy track.
Official sourceFDA press announcement on draft guidance, December 2, 2025
FDAProgram change2025-07-31
ISTAND Established as a Permanent Drug Development Tool Qualification Program
FDA converted the ISTAND initiative (piloted since 2020) into a permanent qualification program for novel drug development tools that do not fit existing DDT categories, including complex in vitro models, organ-on-chip systems, AI-enabled tools, and other NAMs.
- ISTAND is now a standing route rather than a time-limited pilot, so the roadmap's novel-tool qualification pathway should describe it as a permanent program.
- Making the pathway permanent signals durable FDA support for qualifying NAM-based tools for reuse within a defined context of use.
- It sits alongside the established DDT program, keeping ISTAND focused on tools that fall outside existing qualification categories.
Official sourceFDA Voices announcement, July 31, 2025
FDAPolicy roadmap2025-04-10
Roadmap to Reducing Animal Testing in Preclinical Safety Studies
FDA announced a policy shift to reduce or potentially replace animal testing for monoclonal antibodies and other drugs with NAM data, including AI-based computational models, organoid testing, and other human-relevant methods. The agency said implementation would begin immediately for IND applications, where inclusion of NAM data is encouraged, and it planned a pilot program under close FDA consultation.
- This changed the practical review posture for INDs by officially encouraging NAM data in the submission process rather than treating it only as a future possibility.
- The roadmap introduced an FDA pilot pathway for primarily non-animal testing strategies under agency consultation, which is a process change relevant to how sponsors seek acceptance for NAM evidence.
- It also set up later guidance changes, including the December 2025 monoclonal-antibody draft guidance and the March 2026 general NAM validation draft guidance.
Official sourceFDA press announcement and roadmap release, April 10, 2025
ICCVAMValidation framework update2024-03-01
Validation, Qualification, and Regulatory Acceptance of New Approach Methodologies
ICCVAM published an updated validation document replacing the old single-method replacement emphasis with a more flexible framework that can integrate multiple in vitro, in chemico, and in silico approaches to establish confidence for a defined application or context of use.
- This is a real framework change in how cross-agency validation is described: confidence can now come from integrated evidence rather than only from one-for-one animal replacement logic.
- The document strengthens the roadmap's emphasis on context of use, usefulness and limitations, and agency-specific needs and priorities.
- It supports keeping ICCVAM framed as an evidence and evaluation route rather than a simple substitute-method pathway.
Official sourceICCVAM Validation Workgroup document, March 2024